Research Updates

Back to feed
PubMed

High importance

Oct 3, 2026

A Novel GDF2 Mutation in a Patient With Hereditary Hemorrhagic Telangiectasia Complicated by Acute Cerebral Infarction.

View original source

Why it matters

This case enhances the understanding of genetic factors contributing to HHT and emphasizes the need for further research on GDF2 mutations, potentially impacting future diagnostics and therapeutic approaches for patients with HHT.

Objective

To report a case of a patient with a novel GDF2 mutation associated with Hereditary Hemorrhagic Telangiectasia (HHT) complicated by acute cerebral infarction.

Results

The patient exhibited typical symptoms of HHT including recurrent epistaxis and cutaneous vascular lesions. Genetic testing revealed a novel heterozygous frameshift mutation in GDF2, contributing to the patient's HHT diagnosis and ischemic stroke.

Methods

Clinical examination of a 64-year-old female with HHT symptoms was conducted, including family history evaluation and genetic testing for GDF2 mutations.

Limitations

The study is limited to a single case report, which may not generalize to broader HHT populations. There is a lack of longitudinal data regarding the implications of the GDF2 mutation.

For your doctor:

PMID: 42829758

DOI: 10.1002/jha2.70404

Abstract

INTRODUCTION: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease and the growth differentiation factor 2 (GDF2) variants have been identified as an infrequent cause of HHT. CASE REPORT: We report a 64-year-old female patient with an onset of ischemic stroke suspected related with microscopic pulmonary arteriovenous malformations. She had cutaneous vascular lesions, a history of spontaneous recurrent epistaxis, and a family history with her mother exhibiting similar clinical manifestations. The patient was diagnosed with HHT and subsequently found to have a novel heterozygous frameshift mutation of GDF2. CONCLUSION: This case broadens the known clinical spectrum of HHT associated with GDF2 variants.